AIM ImmunoTech says Phase 2 DURIPANC pancreatic cancer trial advances toward Q1 2027 topline data
Bitget2026/10/01 13:04- AIM ImmunoTech highlighted progress in its Phase 2 DURIPANC trial testing Ampligen with AstraZeneca’s Imfinzi in metastatic pancreatic cancer.
- Final Ampligen dosing is complete; topline results will be presented in the first quarter of 2027.
- Interim updates pointed to immune activation signals; treatment has been well-tolerated with patients reporting high quality of life.
- Separate Netherlands named-patient program data in post-FOLFIRINOX maintenance suggested encouraging survival, safety, and quality-of-life outcomes.
- Management positioned upcoming DURIPANC results, including exploratory biomarkers, as input for designing a planned pivotal trial.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Procore director Kevin J. O’Connor disposes of USD 820,090 in common shares
Procore: Director Kevin J. O’Connor reported selling 15,384 common shares on Oct. 5-6. Sales prices ranged from $52.83 to $55.08 per share. Indirect holding fell to 908,286 shares, held via the Kevin J. O’Connor Revocable Trust. O’Connor also reported 21,344 shares held directly. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procore Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-065378), on October 07, 2026, and is solely responsible for the information contained therein.
Microsoft (MSFT.US) launches new flagship laptop! Equipped with Nvidia chips, certain AI tasks outperform Apple MacBook.
Microsoft held a Surface product launch event on Wednesday, announcing the price and release schedule for the new flagship Surface Laptop Ultra equipped with Nvidia chips. Microsoft also stated that the device outperforms competing Apple products in certain artificial intelligence (AI) tasks.
Dan Ives reveals top tech stock picks for 2027! Nvidia, Microsoft, Apple, and three other stocks make the list, Tesla selected as “disruptive tech top pick”
Former Wedbush tech analyst Dan Ives released his top picks for the technology sector in 2027 on Wednesday, listing Nvidia, Microsoft, Palantir, Apple, and CrowdStrike as his five top technology choices.
Crypto prices
More
